Study Investigating the Cardiotoxicity of Anthracyclines in Patients With Diffuse Large B-Cell
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
All patients enrolled in the study will have to be treated with a chemo immunotherapy scheme
R-CHOP with doxorubicin, with doxorubicin analogue or non pegylated liposomal anthracycline
(R-COMP; Sec. 648 DM) administered every 21 days for 6 cycles. In unfavourable patients
(stage II-IV) are allowed 2 additional cycles of rituximab at the end of the 6 cycles of
R-CHOP.